@FiercePharma: Drugmakers rack up $1B in small deals. Article | Follow @FiercePharma
> Johnson & Johnson is looking into possible contamination issues at a South Korean drug facility owned by a company that the American healthcare giant is acquiring. Story
> Hikma Pharmaceuticals, which has just bought Baxter International's U.S. drugs unit, has another $500 million war chest to spend on yet more acquisitions. Article
> Canadian health authorities say GlaxoSmithKline is recalling one lot of Emo-Cort skin lotion because of mold contamination and has halted manufacturing of all Emo-Cort products pending an investigation into the cause. News
> Bayer's blood thinner Xarelto matched the standard therapy at preventing blood clots in patients with an irregular heartbeat, results that may determine its success in a market worth as much as $14 billion. Story
> Pfizer topped the list of America's most generous companies in 2009, according to The Chronicle of Philanthropy, with gifts of cash and products valued at $2.3 billion. Report
> Forest Laboratories won approval Teflaro, a treatment for drug-resistant infections that kill tens of thousands of Americans every year. Story
> The FDA has approved Novartis' Afinitor to treat benign brain tumors. Article
> Astellas Pharma cut its full-year profit forecast a second time, saying earnings will be 13 percent less than predicted because of costs relating to its $4 billion takeover of OSI Pharmaceuticals. Report
> Sun Pharmaceutical Industries, India's biggest drugmaker by market value, said second-quarter profit rose 12 percent on higher demand for generic medicines. Report
> Acorda Therapeutics posted its first quarterly profit in at least three years, surprising Wall Street analysts, on continued robust sales of its key drug Ampyra. Item
Biotech News
@FierceBiotech: Next-gen biotechs pursue 'undruggable' targets. Story | Follow @FierceBiotech
@JohnCFierce: Had a fine time in Boston talking clinical trials with Sanofi, AstraZeneca, Aveo and Cubist Wednesday. Followed up with finance panel in DC Thursday. | Follow @JohnCFierce
> Roche prepares its counterattack against biosimilars. Story
> Waksal making big development plans for his new biotech venture. Article
> Biodel shares plunge after FDA demands two new Ph3 trials. Report
> In bombshell, DOJ reverses stance on gene patents. Item
> Will Avanir drug OK spark takeover attempt? Story
> GSK inks $231M pact for Ph3 Amicus drug. Article
Biotech IT News
> Site provides trial matches, forum for diabetics. Report
> EDC gets cool reception in the clinic. News
> Ovum analyst sees analytics boost in Oracle CDA 2.0. Item
> HHS counts 200 data breaches. Article
> FDA creates IT shopping list for makeover. Story
And Finally... Fifty years after the pill, another birth control revolution may be on the horizon: free contraception for women in the U.S., thanks to the new healthcare law. News